drugset
drugset / Trial / NCT04747145

Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

NCT04747145 ↗

Phase 2 Active not recruiting 38 enrolled Medical College of Wisconsin
NaSingle-groupOpen-labelTreatment

Summary

The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.

Timeline

Start
2021-06-03
Primary completion
2025-03-05
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 —
Subject Temozolomide Small molecule 150 mg/m2 —
Subject Temozolomide Small molecule 200 mg/m2 —

Indications

glioblastoma